Expert Analysis
Expert Analysis: Insights for International Clinicians on New Data From CROI 2020

Released: April 21, 2020

Expiration: April 20, 2021

Josep M. Llibre
Josep M. Llibre, MD, PhD
Laura Waters
Laura Waters, FRCP, MD

Activity

Progress
1
Course Completed
Introduction

Laura Waters, MD:
In this Expert Analysis, Josep M. Llibre, MD, PhD, and I review new data from the 2020 Conference on Retroviruses and Opportunistic Infections (CROI) held virtually March 8-11 from Boston, Massachusetts. In our discussion, we will cover some of the most clinically relevant studies reported, with a focus on how the new findings may affect the practice of clinicians providing care for patients with HIV (PWH) in countries around the world.

Please note that the slide thumbnails in this activity link to a complete PowerPoint slideset that can be found here or downloaded by clicking any of the thumbnails within the activity. 

Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice, once before the discussion that informs the best choice and again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many PWH do you provide care for in a typical week?
Among black patients with viral suppression, what was the effect of baseline NRTI resistance on viral suppression at Week 24 among those switched to bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) vs those who continued 3-drug ART?
In an analysis of the ADVANCE trial, which of the following metabolic outcomes was significantly greater after 96 weeks of dolutegravir (DTG) plus FTC/TAF vs DTG plus FTC/tenofovir disoproxil fumarate (TDF) as initial ART?
The results of the randomized WHIP3TB trial comparing weekly rifapentine plus isoniazid for one 3-month course (3HP) vs weekly rifapentine plus isoniazid for 2 periodic (annual) 3-month courses (p3HP) vs daily isoniazid for 6 months (6H) as tuberculosis (TB) prevention in PWH demonstrated which of the following outcomes?